Biomea Fusion reported positive topline results from a Phase 1 study of its experimental oral obesity drug, BMF-650. In the first four weeks, participants across four outpatient cohorts recorded mean weight reductions of 1.5% to 3.2%, compared with a 0.1% reduction in the placebo group.
The study reported a favorable safety profile among all 40 participants who received BMF-650, with no severe or serious adverse events. Participants tolerated the highest dose, with mild gastrointestinal side effects reported.
Biomea intends to seek a strategic partnership for BMF-650’s late-stage development.